ALK-Abelló A/S

ALK B

DK0061802139

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 10:59:40 2024-05-30 EDT			5-day change	1st Jan Change
150.2 ^DKK	-0.79%		-3.10%	+48.42%

05-30	Alk's European Registration Application for Itulazax for Pneumiatric Indication Accepted for Review	CI
05-03	Transcript : ALK-Abelló A/S, Q1 2024 Earnings Call, May 03, 2024

ALK Announces Resignation of Flemming Pedersen as CFO and Member of the Board of Management By 31 January 2018

July 31, 2017 at 04:12 am

ALK announced that Flemming Pedersen, CFO and member of the Board of Management, has decided to resign his position and leave ALK to join a privately owned Danish company in another industry. Flemming Pedersen will leave ALK by 31 January 2018 at the latest.

Latest news about ALK-Abelló A/S

Alk's European Registration Application for Itulazax for Pneumiatric Indication Accepted for Review	05-30	CI
Transcript : ALK-Abelló A/S, Q1 2024 Earnings Call, May 03, 2024	05-03
ALK-Abelló A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02	CI
ALK-Abelló A/S Updates Revenue Guidance for the Year 2024	05-02	CI
ALK-Abelló A/S Provides Earnings Guidance for the Year 2024	05-02	CI
Transcript : ALK-Abelló A/S - Shareholder/Analyst Call	03-14
New entries in MarketScreener's Europe portfolio	03-04
Transcript : ALK-Abelló A/S, Q4 2023 Earnings Call, Feb 08, 2024	02-08
ALK-Abelló A/S Reports Earnings Results for the Full Year Ended December 31, 2023	02-08	CI
Alk-Abelló A/S Provides Revenue Guidance for the Year of 2024	02-08	CI
ALK-Abelló’s Carbon Reduction Targets Gets Validation from Science-Based Targets Initiative	02-05	MT
Alk's European Registration Application for House Dust Mite Slit-Tablet in Young Children Accepts for Review	01-25	CI
ALK-Abelló’s Peanut Allergy Treatment Shows Safety, Tolerability in First Part of Early-stage Trial	01-18	MT
ALK-Abelló A/S Completes First Part of Phase 1 Trial with Peanut Slit-Tablet	01-18	CI
ALK-Abelló Closes Purchase of US Skin Antigen Test Maker AllerQuest	01-04	MT
ALK-Abelló A/S (CPSE:ALK B) acquired Business Assets of AllerQuest.	01-03	CI
ALK-Abelló A/S Expands Partnership with Torii Pharmaceutical Co., Ltd. in Japan	12-12	CI
Transcript : ALK-Abelló A/S, Q3 2023 Earnings Call, Nov 15, 2023	11-15
Alk-Abelló A/S Provides Earnings Guidance for the Year 2023	11-15	CI
ALK-Abelló A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
ALK Announces Top-Line Results from A Phase 3 Pneumiatric Clinical Trial of Its Sublingual Allergy Immunotherapy Tablet for the Treatment of Tree-Pollen-Induced Allergy Immunotherapy Tablet	23-10-11	CI
Transcript : ALK-Abelló A/S, Q2 2023 Earnings Call, Aug 24, 2023	23-08-24
ALK-Abelló A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
ALK-Abelló A/S Narrows Revenue Guidance for the Full Year 2023	23-08-24	CI
Correction: ALK-Abelló President, CEO to Step Down at 2023-End; Successor Named	23-06-19	MT

Chart ALK-Abelló A/S

Duration

Period

More charts

Company Profile

ALK-Abello A/S is a Denmark-based company active within the pharmaceutical industry. It is engaged in the development and marketing of pharmaceutical products for the treatment, prevention and diagnosis of allergy. Its product portfolio comprises allergy vaccines, emergency treatments and allergy diagnostics products. The Companyâs allergy vaccines product offering comprises tablet vaccines, sublingual vaccines and subcutaneous vaccines. Its emergency treatments product offering comprises products for the management of anaphylaxis. Its allergy diagnostics product offering comprises allergen extracts for allergy testing, such as skin-prick tests. The Company operates worldwide through subsidiaries, production units and distributors in such countries as Austria, Canada, France, Italy, the Netherlands, Poland, Spain, Switzerland, the United States and China.

Sector

Pharmaceuticals

Calendar

2024-06-04 - Capital Markets Day

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ALK-Abelló A/S : No allergy on the horizon

March 12, 2024 at 10:20 am

More Strategies

Ratings for ALK-Abelló A/S

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

151.4 DKK

Average target price

155 DKK

Spread / Average Target

+2.38%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ALK-ABELLÓ A/S	+48.42%	4.85B
ELI LILLY AND COMPANY	+39.82%	731B
NOVO NORDISK A/S	+31.34%	586B
JOHNSON & JOHNSON	-7.31%	348B
MERCK & CO., INC.	+14.23%	319B
ABBVIE INC.	+0.86%	273B
ASTRAZENECA PLC	+13.47%	235B
ROCHE HOLDING AG	-6.63%	203B
NOVARTIS AG	+7.49%	202B
AMGEN INC.	+4.51%	159B

Other Pharmaceuticals

ALK-Abelló A/S

Equities

ALK B

DK0061802139

Pharmaceuticals

ALK Announces Resignation of Flemming Pedersen as CFO and Member of the Board of Management By 31 January 2018

EPS Revisions